CD4 and neoplasm: The results of these analyses reveal that the endogenous CD4+ T cell response to a cross-presented MHC-II-restricted neoantigen is both diverse, involving differentiation into several distinct functional subsets, and dynamic, with the relative frequencies of regulatory and different effector subsets changing over time with progressive tumor growth and in response to therapeutic vaccination.